A Phase 3 interventional study of Voclosporin and Placebo Oral Capsule in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 187 sites in 31 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-27.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 7th largest by enrollment of the 100 interventional ones that give a count, is the only one that started in 2017, is one of 16 in phase 3, and was the 38th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 358 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 8 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.
The aim of the current study is to investigate whether voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 52 weeks. The background therapy will be mycophenolate mofetil (MMF) and initial treatment with IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria (as measured by Urine Protein Creatinine Ratio (UPCR)) while demonstrating an acceptable safety profile.
Key Inclusion Criteria:
OR
OR
Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.
Exclusion Criteria:
Current or medical history of:
Other known clinically significant active medical conditions, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
oral, 23.7 mg twice daily (BID)
Drug: Voclosporin
Voclosporin placebo, oral, 3 capsules twice daily (BID)
Drug: Placebo Oral Capsule
calcineurin inhibitor
Also known as: ISA247
matching placebo capsule
Number of Participants With Adjudicated Renal Response at Week 52
The primary efficacy endpoint was the number of subjects showing renal response at Week 52. Renal response was adjudicated based on blinded data by an independent Clinical Endpoints Committee based on meeting the following criteria * UPCR of ≤0.5 mg/mg \& * eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20% \& * Received no rescue medication for LN \& * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 44 through 52, prior to assessment Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 \& confirmed \>20% drop from baseline) \& have an associated treatment-related or disease-related AE that impacted eGFR Withdrawals prior to Week 52 with insufficient Week 52 data to determine response were defined non responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response
Time frame: 52 Weeks
Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less
Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less
Time frame: 52 Weeks
Time to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days)
Time in days to reduction in Urine Protein Creatinine Ratio to decrease to 0.5 mg/mg or less.
Time frame: 52 Weeks
Number of Participants With Renal Response at Week 24
Number of subjects showing renal response at Week 24. Renal response was adjudicated based on blinded data by an Independent Clinical Endpoints Committee based on the following criteria: UPCR of ≤0.5 mg/mg, \& eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20%, and Received no rescue medication for LN \& Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 16 through 24, just prior to the renal response assessment. Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 AND confirmed \>20% drop from BL) \& have an associated treatment-related or disease-related AE that impacted eGFR. Subjects who withdrew prior to the Week 24 assessment and provided insufficient Week 24 data to determine response were defined as non-responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response.
Time frame: Week 24
Number of Subjects With Partial Renal Response at Weeks 24 & 52
Number of subjects with partial Renal Response (defined as a 50% reduction in UPCR from baseline) at Week 24 and at Week 52. Baseline UPCR is the average of 2 pre-randomisation values.
Time frame: Weeks 24 and 52
Number of Subjects Achieving, and Remaining in, Renal Response (Urine Protein Creatinine Ratio ≤0.5 mg/mg)
Number of subjects achieving, and remaining in, renal response (Urine Protein Creatinine ratio ≤0.5 mg/mg)
Time frame: Week 52
Duration of Renal Response (Number of Days)
Duration in days until second occurrence of UPCR \>0.5 mg/mg in those subjects who achieve a reduction in UPCR to below 0.5 mg/mg
Time frame: Week 52
Number of Subjects Achieving 50% Reduction in Urine Protein Creatinine Ratio
Number of subjects achieving 50% reduction in Urine Protein Creatinine ratio
Time frame: 52 Weeks
Time to 50% Reduction in UPCR (Number of Days)
Time in days to reduction in Urine Protein Creatinine Ratio to decrease by 50% compared to baseline. Baseline is the average of two pre-randomisation values.
Time frame: 52 weeks
Change From Baseline in eGFR
Change from baseline by visit in estimated Glomerular Filtration rate. eGFR is corrected to a maximum value of 90 mL/min/1.73 m2
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 16, 20, 24, 30, 36, 42, 48 and 52.
Change From Baseline in UPCR
Change from baseline by visit in Urine Protein Creatinine Ratio. Baseline is the average of two pre-randomisation values.
Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 16, 20, 24, 30, 36, 42, 48 and 52.
Number of Subjects With Renal Response With Low Dose Steroids
Programmed Renal Response whilst on low dose steroids (\<2.5 mg/day) for the preceding 8 Weeks at Weeks 24 and 52
Time frame: Week 24 and Week 52
Change From Baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA - SLEDAI)
Change from baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at Week 24 and 52. The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.
Time frame: Week 24 and Week 52
Change From Baseline in Patient Reported Outcomes
Health-related quality of life (HRQoL) information was collected using the Short Form Health Survey (SF-36) HRQoL assessment and the LupusPRO (v1.7) assessment. The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. Scoring ranges from 0 to 100 with higher scores reflecting better health. LupusPro assessment is a patient-reported questionnaire regarding the effect of lupus or its treatment on the patient's health, quality of life, and the medical care received related to lupus. The questionnaire consists of 43 questions within 8 HRQOL domains and 4 Non-HRQoL domains. Scores range from 0 to 100 with higher scores reflecting better quality of life.
Time frame: Week 24 and Week 52
Eligible subjects were randomized in a ratio of 1:1 to receive either voclosporin 23.7 mg twice daily (BID) or matching placebo for 52 weeks. All subjects were also to receive 2 g/day mycophenolate mofetil (MMF). In addition, all subjects were to receive 0.5 g/day intravenous (IV) methylprednisolone on Days 1 and 2 before changing to a reducing course of oral corticosteroid therapy on Day 3.
| Milestone | Voclosporin | Placebo |
|---|---|---|
| Started | 179 | 178 |
| Week 24 | 167 | 162 |
| Week 52 | 162 | 147 |
| Completed | 163 | 147 |
| Not completed | 16 | 31 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 1 | 5 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 14 |
| Withdrew: Prohibited medication required | 1 | 0 |
| Withdrew: Protocol non-compliance | 1 | 1 |
| Withdrew: None of the above | 0 | 4 |
| Withdrew: Adverse event (ae) prior to first dose | 1 | 0 |
The primary efficacy endpoint was the number of subjects showing renal response at Week 52. Renal response was adjudicated based on blinded data by an independent Clinical Endpoints Committee based on meeting the following criteria * UPCR of ≤0.5 mg/mg \& * eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20% \& * Received no rescue medication for LN \& * Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 44 through 52, prior to assessment Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 \& confirmed \>20% drop from baseline) \& have an associated treatment-related or disease-related AE that impacted eGFR Withdrawals prior to Week 52 with insufficient Week 52 data to determine response were defined non responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Number of renal responders | 73 | 40 |
| Number of renal non-responders | 106 | 138 |
Number of Participants With Reduction in Urine Protein Creatinine Ratio to 0.5 mg/mg or Less
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Subjects with UPCR ≤ 0.5 | 116 | 78 |
| Subjects without UPCR ≤ 0.5 | 63 | 100 |
Time in days to reduction in Urine Protein Creatinine Ratio to decrease to 0.5 mg/mg or less.
| days | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Time to Urine Protein Creatinine Ratio of ≤0.5 mg/mg (Number of Days) | 169 (141 to 214) | 372 (295 to NA) |
Number of subjects showing renal response at Week 24. Renal response was adjudicated based on blinded data by an Independent Clinical Endpoints Committee based on the following criteria: UPCR of ≤0.5 mg/mg, \& eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of \>20%, and Received no rescue medication for LN \& Did not receive more than 10 mg prednisone for ≥3 consecutive days or for ≥7 days in total during Weeks 16 through 24, just prior to the renal response assessment. Note:To be disqualified from renal response, the subject had to fail both eGFR measures (i.e., confirmed eGFR \<60 mL/min/1.73 m2 AND confirmed \>20% drop from BL) \& have an associated treatment-related or disease-related AE that impacted eGFR. Subjects who withdrew prior to the Week 24 assessment and provided insufficient Week 24 data to determine response were defined as non-responders. Subjects who discontinued study drug but continued to attend study visits had their data assessed for response.
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Number of renal responders | 58 | 35 |
| Number of renal non-responders | 121 | 143 |
Number of subjects with partial Renal Response (defined as a 50% reduction in UPCR from baseline) at Week 24 and at Week 52. Baseline UPCR is the average of 2 pre-randomisation values.
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Week 24 | 126 | 89 |
| Week 52 | 125 | 92 |
Number of subjects achieving, and remaining in, renal response (Urine Protein Creatinine ratio ≤0.5 mg/mg)
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Subjects achieving UPCR ≤ 0.5 mg/mg | 116 | 78 |
| number with 2nd occurrence of UPCR > 0.5 mg/mg | 53 | 37 |
| number without 2nd occurrence of UPCR > 0.5 mg/mg | 63 | 41 |
Duration in days until second occurrence of UPCR \>0.5 mg/mg in those subjects who achieve a reduction in UPCR to below 0.5 mg/mg
| days | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Duration of Renal Response (Number of Days) | 216 (127 to NA) | 198 (103 to NA) |
Number of subjects achieving 50% reduction in Urine Protein Creatinine ratio
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Subjects with 50% UPCR reduction | 173 | 135 |
| Subjects without 50% UPCR reduction | 6 | 43 |
Time in days to reduction in Urine Protein Creatinine Ratio to decrease by 50% compared to baseline. Baseline is the average of two pre-randomisation values.
| days | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Time to 50% Reduction in UPCR (Number of Days) | 29 (29 to 32) | 63 (57 to 87) |
Change from baseline by visit in estimated Glomerular Filtration rate. eGFR is corrected to a maximum value of 90 mL/min/1.73 m2
| ml/min/1.73 square metres | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Baseline | 78.3 ± 15.83 | 77.4 ± 16.98 |
| Week 2 change from baseline | -1.5 ± 9.44 | 3.3 ± 10.12 |
| Week 4 change from baseline | -0.4 ± 10.39 | 3.2 ± 9.86 |
| Week 8 change from baseline | -0.9 ± 13.1 | 3.8 ± 11.27 |
| Week 12 change from baseline | -0.3 ± 11.74 | 3.3 ± 12.85 |
| Week 16 change from baseline | -0.1 ± 12.27 | 2.8 ± 13.25 |
| Week 20 change from baseline | -0.7 ± 12.09 | 3.2 ± 13.04 |
| Week 24 change from baseline | -0.3 ± 13.8 | 2.8 ± 13.84 |
| Week 30 change from baseline | -0.8 ± 14.2 | 1.8 ± 14.4 |
| Week 36 change from baseline | -1.9 ± 14.89 | 1.5 ± 14.84 |
| Week 42 change from baseline | -2.8 ± 16.7 | 1.5 ± 15.53 |
| Week 48 change from baseline | -3.6 ± 17.2 | 1.1 ± 15.71 |
| Week 52 change from baseline | -1.5 ± 16.16 | 1.5 ± 15 |
Change from baseline by visit in Urine Protein Creatinine Ratio. Baseline is the average of two pre-randomisation values.
| mg/mg | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Baseline | 4.14 ± 2.711 | 3.87 ± 2.363 |
| Week 2 change from baseline | -1.46 ± 1.991 | -0.7 ± 2.312 |
| Week 4 change from baseline | -1.98 ± 2.29 | -1.07 ± 2.155 |
| Week 8 change from baseline | -2.23 ± 2.213 | -1.43 ± 2.448 |
| Week 12 change from baseline | -2.56 ± 2.293 | -1.48 ± 2.688 |
| Week 16 change from baseline | -2.75 ± 2.462 | -1.58 ± 2.81 |
| Week 20 change from baseline | -2.74 ± 2.968 | -1.54 ± 2.82 |
| Week 24 change from baseline | -2.74 ± 2.567 | -1.59 ± 2.899 |
| Week 30 change from baseline | -2.66 ± 3.336 | -1.7 ± 3.112 |
| Week 36 change from baseline | -2.74 ± 2.871 | -1.63 ± 3.188 |
| Week 42 change from baseline | -2.91 ± 2.522 | -1.78 ± 3.39 |
| Week 48 change from baseline | -2.71 ± 2.807 | -1.8 ± 3.004 |
| Week 52 change from baseline | -2.65 ± 2.872 | -1.88 ± 3.05 |
Programmed Renal Response whilst on low dose steroids (\<2.5 mg/day) for the preceding 8 Weeks at Weeks 24 and 52
| Participants | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Renal Response at Week 24 | 32 | 16 |
| Renal Response at Week 52 | 64 | 36 |
Change from baseline in Safety of Estrogens in Systemic Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at Week 24 and 52. The SELENA-SLEDAI tool is a cumulative and weighted index used to assess disease activity across 24 different disease descriptors in patients with lupus. A patient's SELENA-SLEDAI total score is the sum of all marked lupus related descriptors (seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, cerebrovascular accident, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, leukopenia). A total score can fall between 0 and 105, with a higher score representing a more significant degree of disease activity.
| scores on a scale | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Change from baseline at Week 24 | -4.5 (-5.4 to -3.7) | -4.1 (-5.0 to -3.2) |
| Change from baseline at Week 52 | -6 (-6.7 to -5.2) | -5.5 (-6.3 to -4.7) |
Health-related quality of life (HRQoL) information was collected using the Short Form Health Survey (SF-36) HRQoL assessment and the LupusPRO (v1.7) assessment. The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. Scoring ranges from 0 to 100 with higher scores reflecting better health. LupusPro assessment is a patient-reported questionnaire regarding the effect of lupus or its treatment on the patient's health, quality of life, and the medical care received related to lupus. The questionnaire consists of 43 questions within 8 HRQOL domains and 4 Non-HRQoL domains. Scores range from 0 to 100 with higher scores reflecting better quality of life.
| score on a scale | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| SF-36 change from baseline at Week 24 | 6.64 (4.34 to 8.93) | 7.11 (4.80 to 9.42) |
| SF-36 change from baseline at Week 52 | 10.44 (8.04 to 12.83) | 10.81 (8.37 to 13.25) |
| LupusPRO HRQOL change from baseline at Week 24 | 7.7 (5.40 to 10.13) | 6.06 (3.68 to 8.45) |
| LupusPRO HRQOL change from baseline at Week 52 | 9.24 (6.78 to 11.70) | 9.84 (7.33 to 12.35) |
| LupusPRO non-HRQOL change from baseline at Week 24 | 1.06 (-1.32 to 3.44) | 2.94 (0.54 to 5.35) |
| LupusPRO non-HRQOL change from baseline at Week 52 | 4.08 (1.60 to 6.56) | 3.74 (1.22 to 6.26) |
Collected over Reporting period is from first dose up to 30 days following last dose (Week 52).. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voclosporin | 1/178 (0.6%) | 37/178 (20.8%) | 161/178 (90.4%) |
| Placebo Oral Capsule | 5/178 (2.8%) | 38/178 (21.3%) | 156/178 (87.6%) |
| Event | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| PneumoniaInfections and infestations | 7/178 | 8/178 |
| Acute kidney injuryRenal and urinary disorders | 4/178 | 2/178 |
| Lupus nephritisRenal and urinary disorders | 1/178 | 4/178 |
| GastroenteritisInfections and infestations | 3/178 | 0/178 |
| BronchitisInfections and infestations | 0/178 | 3/178 |
| AnaemiaBlood and lymphatic system disorders | 3/178 | 0/178 |
| HypertensionVascular disorders | 3/178 | 1/178 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 3/178 | 3/178 |
| Urinary tract infectionInfections and infestations | 2/178 | 1/178 |
| Renal impairmentRenal and urinary disorders | 2/178 | 1/178 |
| Event | Voclosporin | Placebo Oral Capsule |
|---|---|---|
| Glomerular filtration rate decreasedInvestigations | 43/178 | 15/178 |
| HypertensionVascular disorders | 35/178 | 14/178 |
| DiarrhoeaGastrointestinal disorders | 34/178 | 21/178 |
| Upper respiratory tract infectionInfections and infestations | 31/178 | 26/178 |
| HeadacheNervous system disorders | 29/178 | 11/178 |
| Viral upper respiratory tract infectionInfections and infestations | 20/178 | 18/178 |
| AnaemiaBlood and lymphatic system disorders | 18/178 | 10/178 |
| Urinary tract infectionInfections and infestations | 17/178 | 13/178 |
| NauseaGastrointestinal disorders | 10/178 | 17/178 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/178 | 17/178 |
Intent-to-Treat is comprised of all subjects who were randomized treatment, and was used for analysis of all Outcome Measures. Safety population comprised all randomized subjects who took at least one dose of study treatment, and was used for AE and SAE reporting. 1 Voclosporin subject was withdrawn due to an adverse event (AE) prior to receiving the first dose of Voclosporin.
| Age, Continuous(years) | Voclosporin | Placebo | Total |
|---|---|---|---|
| Mean | 32.8 ± 10.93 | 33.6 ± 11 | 33.2 ± 10.96 |
| Sex: Female, Male(Participants) | Voclosporin | Placebo | Total |
|---|---|---|---|
| Female | 161 | 152 | 313 |
| Male | 18 | 26 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Voclosporin | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 57 | 59 | 116 |
| Not Hispanic or Latino | 122 | 118 | 240 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Voclosporin | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 4 | 4 |
| Asian | 53 | 56 | 109 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 21 | 13 | 34 |
| White | 68 | 61 | 129 |
| More than one race | 37 | 44 | 81 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Voclosporin | Placebo | Total |
|---|---|---|---|
| United States | 26 | 26 | 52 |
| Southeast Asia | 52 | 52 | 104 |
| Europe | 52 | 52 | 104 |
| South America | 49 | 48 | 97 |
| Lupus Nephritis (LN) history(years) | Voclosporin | Placebo | Total |
|---|---|---|---|
| Years since diagnosis of systemic lupus erythematosus (SLE) | 6.6 ± 6.41 | 6.9 ± 6.07 | 6.7 ± 6.23 |
| Years since diagnosis of LN | 4.6 ± 5.07 | 4.7 ± 4.89 | 4.6 ± 4.97 |
| Years since first Proteinuria | 4.8 ± 5.2 | 4.6 ± 4.51 | 4.7 ± 4.86 |
| Baseline Urine Protein Creatinine Ratio (UPCR)(mg/mg) | Voclosporin | Placebo | Total |
|---|---|---|---|
| Median | 4.14 ± 2.711 | 3.87 ± 2.363 | 4.00 ± 2.537 |
| Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73 m2) | Voclosporin | Placebo | Total |
|---|---|---|---|
| Median | 92.1 ± 30.06 | 90.4 ± 28.97 | 91.2 ± 29.51 |
Showing the first 100 of 187 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Sep 2019, 28 months.
Results were first posted in Jun 2021, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Aurinia Pharmaceuticals Inc.